Matching articles for "Issue 1282"
Issue 1282 · March 24, 2008
A Rivastigmine Patch for Dementia

Cholinesterase inhibitors are now used routinely in patients with dementia. Rivastigmine transdermal system ( Exelon Patch - Novartis), a patch formulation of the cholinesterase inhibitor rivastigmine…

Med Lett Drugs Ther. 2008 Mar 24; 50(1282):21-2
Cholinesterase inhibitors are now used routinely in patients with dementia. Rivastigmine transdermal system ( Exelon Patch - Novartis), a patch formulation of the cholinesterase inhibitor rivastigmine tartrate, has been approved by the FDA for treatment of mild to moderate dementia associated with Alzheimer's or Parkinson's disease. An oral formulation of rivastigmine tartrate has been available in the US since 2000,2 but gastrointestinal adverse effects possibly related to rapidly rising serum concentrations have limited its use.
Issue 1282 · March 24, 2008
Palatal Implants for Snoring and Obstructive Sleep Apnea

Treatment options for snoring and obstructive sleep apnea (OSA) now include, in addition to lifestyle remedies such as weight loss and avoidance of alcohol in the evening, mechanical devices, injection of…

Med Lett Drugs Ther. 2008 Mar 24; 50(1282):23-4
Treatment options for snoring and obstructive sleep apnea (OSA) now include, in addition to lifestyle remedies such as weight loss and avoidance of alcohol in the evening, mechanical devices, injection of botulinum toxin into the soft palate and a variety of ENT surgical outpatient procedures. Palatal implants ( Pillar procedure - Restore Medical Inc) have been approved by the FDA for treatment of snoring and OSA.
Issue 1282 · March 24, 2008 Free
In Brief: Influenza Developments

Recent reports (D Kaye.Clin Infect Dis April 1, 2008;46:iii) indicate that 2 of the 3 components of this year's influenza vaccine (Med Lett Drugs Ther 2007;49:81) , the influenza B and A/H3N2 antigens, do not…

Med Lett Drugs Ther. 2008 Mar 24; 50(1282):21-4
Recent reports (D Kaye.Clin Infect Dis April 1, 2008;46:iii) indicate that 2 of the 3 components of this year's influenza vaccine (Med Lett Drugs Ther 2007;49:81) , the influenza B and A/H3N2 antigens, do not matchup well with circulating strains. The B component is probably not protective. The A/H3N2 antigen in the vaccine probably provides some protection, particularly for high-risk patients. The third component, the A/H1N1 antigen, is protective against circulating A/H1N1 influenza viruses, but these viruses, unlike previous A/H1N1 strains, are developing some resistance to oseltamivir ( Tamiflu ), particularly in Europe; in the US and Canada, about 5% of influenza A/H1N1 isolates are resistant to oseltamivir in vitro . Download U.S. English